Skip to main content
. Author manuscript; available in PMC: 2024 Apr 12.
Published in final edited form as: J Psychopharmacol. 2017 Feb 15;31(4):434–441. doi: 10.1177/0269881117691590

Table 2.

Pharmacokinetic parameters of AVL-3288

Kel1 (Hr1) Kel1 (Hr1) Kabs (Hr1) AUC (ng/mL•Hr) Calculated Half-Life Kel1 (Hr) Calculated Half-Life Kel2 (Hr) Observed Cmax (ng/mL) Calculated Tmax (Hr)
3 mg mean 0.26 2.63 385 2.87 79.3 1
SD 0.08 0.70 108 0.78 21.3 0.2
10 mg mean 0.45 0.07 1.86 1488 2.45 24.8* 239.0 1.1
SD 0.32 0.07 0.53 764 2.16 26.2 55.8 0.3
30 mg mean 0.25 .005 2.09 4231 2.83 222.3* 310.73 1.3
SD 0.10 .003 0.92 1763 1.02 201.8 80.6 0.5
*

The difference in half-life between 10 and 30 mg is a result of the limitation of the assay for the LCMS method with the levels at the lower dose being closer to the lower limit of quantitation.